Akebia Therapeutics, Inc. develops and commercializes therapeutics for people impacted by kidney disease. Company news commonly covers Vafseo® (vadadustat), an oral HIF-PH inhibitor indicated for anemia due to chronic kidney disease in adults receiving dialysis, and Auryxia® (ferric citrate), a U.S.-marketed therapy for chronic kidney disease-related conditions.
Recurring updates also address product revenue, dialysis-market access, clinical data publications, and kidney disease pipeline programs, including praliciguat in focal segmental glomerulosclerosis, AKB-097 in rare kidney diseases, and AKB-9090 for cardiac surgery-associated acute kidney injury. Akebia also reports Nasdaq inducement grants, board changes, investor presentations, and quarterly financial results.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has announced its participation in two upcoming investor conferences in September 2024. The company's executives will attend the Wells Fargo Healthcare Conference in Boston from September 4-6 and the H.C. Wainwright 26th Annual Global Investment Conference in New York from September 9-11.
CEO John Butler will present at both events:
- Wells Fargo Healthcare Conference: Friday, September 6 at 9:30 a.m. EST
- H.C. Wainwright Global Investment Conference: Monday, September 9 at 10:30 a.m. EST (fireside chat)
Webcasts of both presentations will be available through Akebia's investor relations website for approximately 90 days following the conferences.
Akebia Therapeutics reported its Q2 2024 financial results, revealing a net loss of $8.6M, an improvement from $11.2M in the same quarter last year. Total revenues dropped to $43.6M from $56.4M, mainly due to a decrease in license, collaboration, and other revenues. Net product revenues stood at $41.2M, a slight decline from $42.2M in Q2 2023. Research & Development expenses significantly decreased to $7.6M from $20.2M due to the completion of certain clinical trials. The company set the WAC for its recently FDA-approved Vafseo® at $1,278 for a 30-day supply, with sales expected to begin in January 2025. Akebia expects its existing cash resources and operations to fund its activities for at least two years.
Akebia Therapeutics (Nasdaq: AKBA) has announced plans to release its financial results for the second quarter of 2024 on Thursday, August 8, 2024, before the financial markets open. The company will host a conference call at 8:00 a.m. ET on the same day to discuss the results and recent business highlights.
Investors and interested parties can access the call by dialing (800) 715-9871 (USA & Canada - Toll-Free) and entering Conference ID: 4155557. Additionally, a live webcast of the conference call will be available through the Investors section of Akebia's website at https://ir.akebia.com/. An online archive of the webcast will also be accessible via the same section of the company's website.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has granted stock options to three newly-hired employees as part of their employment inducement. The grants, made on July 31, 2024, include options to purchase a total of 47,000 shares of Akebia's common stock at an exercise price of $1.38 per share, which matches the closing price on the grant date.
These options vest over a four-year period, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. Each option has a 10-year term and is subject to Akebia's inducement award program and specific stock option agreements.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has announced its participation in two upcoming investor conferences in August 2024. The company will be present at the BTIG virtual Biotechnology Conference from August 5-6 and the Canaccord Genuity 44th Annual Growth Conference in Boston from August 13-14.
CEO John Butler will participate in a fireside chat at the BTIG conference on August 6 at 8:00 am EST. At the Canaccord Genuity conference, Mr. Butler will deliver a presentation on August 14 at 8:30 a.m. EST. Investors can access a webcast of the Canaccord Genuity presentation through Akebia's website after the conference.
Akebia Therapeutics has announced significant updates for the commercial launch of Vafseo® (vadadustat) Tablets. Following a termination agreement with CSL Vifor, Akebia now holds full rights to sell Vafseo in the U.S. The Wholesale Acquisition Cost (WAC) has been set at $1,278 for a 30-day supply. Akebia has submitted a TDAPA application for Vafseo, anticipating designation by January 1, 2025. The company aims to finalize contracts with dialysis providers covering the majority of eligible patients by the end of 2024. Additionally, Akebia will host a conference call on July 11, 2024, at 8:00 a.m. ET to discuss these updates.
Akebia Therapeutics (Nasdaq: AKBA) announced inducement grants under Nasdaq Listing Rule 5635(c)(4) for five newly-hired employees. The grants include options to purchase a total of 517,000 shares of common stock, with 500,000 shares allocated to Erik Ostrowski, the new CFO and Chief Business Officer. The exercise price for these options is $1.02 per share, matching the closing price on the grant date, June 28, 2024. These options have a 10-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting quarterly. The grants are part of Akebia’s inducement award program.
Akebia Therapeutics, a biopharmaceutical company focused on improving the lives of people with kidney disease, announced that its CEO, John Butler, will participate in the H.C. Wainwright 3rd Annual Kidney Virtual Conference.
The event is set for Monday, July 15, 2024, at 9:30 a.m. ET. During the conference, Butler will provide updates on the commercial launch activities for Vafseo (vadadustat) Tablets.
Interested parties can access a webcast of the presentation through the Investors section of Akebia's website for 30 days following the event. This conference is an important platform for Akebia to showcase its advancements and strategies in the kidney disease sector.
Akebia Therapeutics, a biopharmaceutical company focusing on kidney disease treatments, announced the appointment of Erik Ostrowski as Senior Vice President, Chief Financial Officer, and Chief Business Officer.
Mr. Ostrowski, an experienced biotech executive, joins Akebia from Avrobio, where he played a key role in its merger with Tectonic Therapeutic. Previously, he was instrumental in the IPO of Summit Therapeutics and served on the Board of Directors of Faron Pharmaceuticals.
CEO John P. Butler expressed confidence in Ostrowski's leadership, emphasizing the company's strong financial position as it launches Vafseo® (vadadustat) Tablets.
Ostrowski holds degrees from Babson College and the University of Chicago Booth School of Business. He expressed enthusiasm about joining Akebia, highlighting its established revenue-generating business and promising pipeline.
Akebia Therapeutics, a biopharmaceutical company focused on kidney disease, announced on June 3, 2024, that it granted stock options to four newly-hired employees. The options, amounting to 76,000 shares with an exercise price of $1.12 per share, were granted on May 31, 2024, under Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting quarterly thereafter. Each option has a 10-year term and is subject to Akebia's inducement award program and stock option agreement.